ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?

Key Takeaways ABBV offsets Humira losses with Skyrizi and Rinvoq, driving strong sales growth in 2025.MRK leans on Keytruda but faces declining Gardasil sales and other vaccine headwinds.ABBVs rising estimates, robust pipeline and stock gains position it ahead of MRK in 2025.Merck (MRK) and AbbVie (ABBV) are prominent pharmaceutical companies with strong positions in oncology and immunology.AbbVie also operates in aesthetics, neuroscience and eye care, while Merck has a broader focus that includes vaccines, ...